KalVista Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KALV research report →
About the company
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa.
- CEO
- Benjamin L. Palleiko
- IPO
- 2015
- Employees
- 275
- HQ
- Framingham, MA, US
Price Chart
- Market Cap
- $1.44B
- P/E
- -8.36
- P/S
- 12.40
- P/B
- -503.31
- EV/EBITDA
- -12.74
- Div Yield
- 0.00%
- Gross Margin
- 92.03%
- Op Margin
- -120.80%
- Net Margin
- -119.44%
- ROE
- -1057.44%
- ROIC
- -46.81%
- Revenue
- $73.62M · 0.00%
- Net Income
- $-164,286,000 · 10.44%
- EPS
- $-3.23 · 12.47%
- Op Income
- $-171,838,500
- FCF YoY
- 45.66%
- 52W High
- $27.00
- 52W Low
- $9.83
- 50D MA
- $24.43
- 200D MA
- $17.09
- Beta
- -0.29
- Avg Volume
- 3.63M
Get TickerSpark's AI analysis on KALV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Stuart Nancy | sell | 14,000 |
| Jun 11, 26 | Stuart Nancy | sell | 10,000 |
| Jun 11, 26 | Stuart Nancy | sell | 10,000 |
| Jun 11, 26 | Stuart Nancy | sell | 10,000 |
| Jun 11, 26 | Stuart Nancy | sell | 30,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 14,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 7,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 10,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 10,000 |
| Jun 11, 26 | Pereira Brian JG | sell | 10,000 |
Our KALV coverage
Recent articles, reports, and earnings notes.
No research on KALV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KALV report →Similar companies
Peers in the same neighborhood.